|
1
|
Pennock S, Haddock LJ, Eliott D, Mukai S
and Kazlauskas A: Is neutralizing vitreal growth factors aviable
strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye
Res. 40:16–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Umazume K, Tsukahara R, Liu L, Fernandez
de Castro JP, McDonald K, Kaplan HJ and Tamiya S: Role of retinal
pigment epithelial cell β-catenin signaling in experimental
proliferative vitreoretinopathy. Am J Pathol. 184:1419–1428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tosi GM, Marigliani D, Romeo N and Toti P:
Disease pathways in proliferative vitreoretinopathy: An ongoing
challenge. J Cell Physiol. 229:1577–1583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li H, Wang H, Wang F, Gu Q and Xu X: Snail
involves in the transforming growth factor β1-mediated
epithelial-mesenchymal transition of retinal pigment epithelial
cells. PLoS One. 6:e233222011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang S, Li H, Li M and Wang F: Mechanisms
of epithelial-mesenchymal transition in proliferative
vitreoretinopathy. Discov Med. 20:207–217. 2015.PubMed/NCBI
|
|
7
|
Zhang J, Tian XJ, Zhang H, Teng Y, Li R,
Bai F, Elankumaran S and Xing J: TGF-β-induced
epithelial-to-mesenchymal transition proceeds through stepwise
activation of multiple feedback loops. Sci Signal. 7:ra912014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bochaton-Piallat ML, Kapetanios AD, Donati
G, Redard M, Gabbiani G and Pournaras CJ: TGF-beta1, TGF-beta
receptor II and ED-A fibronectin expression in myofibroblast of
vitreoretinopathy. Invest Ophthalmol Vis Sci. 41:2336–2342.
2000.PubMed/NCBI
|
|
9
|
Asaria RH, Kon CH, Bunce C, Sethi CS, Limb
GA, Khaw PT, Aylward GW and Charteris DG: Silicone oil concentrates
fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol.
88:1439–1442. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoerster R, Muether PS, Vierkotten S,
Hermann MM, Kirchhof B and Fauser S: Upregulation of TGF-ß1 in
experimental proliferative vitreoretinopathy is accompanied by
epithelial to mesenchymal transition. Graefes Arch Clin Exp
Ophthalmol. 252:11–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang CM, Tai MC, Chang YH, Chen YH, Chen
CL, Lu DW and Chen JT: Glucosamine inhibits
epithelial-to-mesenchymal transition and migration of retinal
pigment epithelium cells in culture and morphologic changes in a
mouse model of proliferative vitreoretinopathy. Acta Ophthalmol.
89:e505–e514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nassar K and Grisanti S, Tura A, Lüke J,
Lüke M, Soliman M and Grisanti S: A TGF-β receptor 1 inhibitor for
prevention of proliferative vitreoretinopathy. Exp Eye Res.
123:72–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dvashi Z, Goldberg M, Adir O, Shapira M
and Pollack A: TGF-β1 induced transdifferentiation of RPE cells is
mediated by TAK1. PLoS One. 10:e01222292015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saika S, Kono-Saika S, Tanaka T, Yamanaka
O, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Yoo J, Flanders KC and
Roberts AB: Smad3 is required for dedifferentiation of retinal
pigment epithelium following retinal detachment in mice. Lab
Invest. 84:1245–1258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garweg JG, Tappeiner C and Halberstadt M:
Pathophysiology of proliferative vitreoretinopathy in retinal
detachment. Surv Ophthalmol. 58:321–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Peng R, Chen H, Cui C and Ba J:
Elucidation of the pathogenic mechanism of rhegmatogenous retinal
detachment with proliferative vitreoretinopathy by proteomic
analysis. Invest Ophthalmol Vis Sci. 53:8146–8153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao HM, Yu J, Sheng MJ and Wang KS:
Experimental study of kallikrein-kinin system participating in
proliferative vitreoretinopathy procedure. Chin J Exp Ophthalmol.
29:591–595. 2011.(In Chinese).
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saika S, Yamanaka O, Okada Y, Tanaka S,
Miyamoto T, Sumioka T, Kitano A, Shirai K and Ikeda K: TGF-beta in
fibroproliferative diseases in the eye. Front Biosci (Schol Ed).
1:376–390. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai Y, Lu H, Lin C, Xu Y, Hu D, Liang Y,
Hong W and Chen B: Sonic hedgehog-mediated epithelial-mesenchymal
transition in renal tubulointerstitial fibrosis. Int J Mol Med.
37:1317–1327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao YL, Zhu RT and Sun YL:
Epithelial-mesenchymal transition in liver fibrosis. Biomed Rep.
4:269–274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu TJ, Chang SS, Li CW, Hsu YH, Chen TC,
Lee WC, Yeh CT and Hung MC: Severe hepatitis promotes
hepatocellular carcinoma recurrence via NF-κB pathway-mediated
epithelial-mesenchymal transition after resection. Clin Cancer Res.
22:1800–1812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong SK, Park JR, Kwon OS, Kim KT, Bae GY
and Cha HJ: Induction of integrin β3 by sustained ERK activity
promotes the invasiveness of TGFβ-induced mesenchymal tumor cells.
Cancer Lett. 376:339–346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Massagué J: TGF-beta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han L, Zhang HW, Zhou WP, Chen GM and Guo
KJ: The effects of genistein on transforming growth
factor-β1-induced invasion and metastasis in human pancreatic
cancer cell line Panc-1 in vitro. Chin Med J (Engl). 125:2032–2040.
2012.PubMed/NCBI
|
|
26
|
Koeck S, Amann A, Huber JM, Gamerith G,
Hilbe W and Zwierzina H: The impact of metformin and salinomycin on
transforming growth factor β-induced epithelial-to-mesenchymal
transition in non-small cell lung cancer cell lines. Oncol Lett.
11:2946–2952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang S, Yao H, Li M, Li H and Wang F: Long
non-coding RNA MALAT1 mediates transforming growth factor
beta1-induced epithelial-mesenchymal transition of retinal pigment
epithelial cells. PLoS One. 11:e01526872016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Masszi A, Fan L, Rosivall L, McCulloch CA,
Rotstein OD, Mucsi I and Kapus A: Integrity of cell-cell contacts
is a critical regulator of TGF-beta 1-induced
epithelial-to-myofibroblast transition: Role for beta-catenin. Am J
Pathol. 165:1955–1967. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Palma-Nicolás JP and López-Colomé AM:
Thrombin induces slug-mediated E-cadherin transcriptional
repression and the parallel up-regulation of N-cadherin by a
transcription-independent mechanism in RPE cells. J Cell Physiol.
228:581–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Priglinger CS and Priglinger S:
Pharmacological approach to treatment of proliferative
vitreoretinopathy. Ophthalmology. 110:948–959. 2013.(In German).
View Article : Google Scholar
|
|
32
|
Mandava N, Blackburn P, Paul DB, Wilson
MW, Read SB, Alspaugh E, Tritz R, Barber JR, Robbins JM and Kruse
CA: Ribozyme to proliferating cell nuclear antigen to treat
proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci.
43:3338–3348. 2002.PubMed/NCBI
|
|
33
|
Chen W, Chen H, Hou P, Fok A, Hu Y and Lam
DS: Midterm results of low-dose intravitreal triamcinolone as
adjunctive treatment for proliferative vitreoretinopathy. Retina.
31:1137–1142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yarovaya GA and Neshkova EA:
Kallikrein-Kinin system. Long history and present. (To 90th
Anniversary of Discovery of the System). Bioorg Khim. 41:275–291.
2015.(In Russian).
|
|
35
|
Wang T, Tang Y and Lou JS: Advances in
research on kallikrein-kinin system in cardiovascular system. Chin
J Pharmacol Toxicol. 17:466–470. 2003.
|
|
36
|
Yu J, Peng R, Chen H, Cui C, Ba J and Wang
F: Kininogen 1 and insulin-like growth factor binding protein 6:
Candidate serum biomarkers of proliferative vitreoretinopathy. Clin
Exp Optom. 97:72–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leeb-Lundberg LM, Marceau F, Müller-Esterl
W, Pettibone DJ and Zuraw BL: International union of pharmacology.
XLV. Classification of the kinin receptor family: From molecular
mechanisms to pathophysiological consequences. Pharmacol Rev.
57:27–77. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cárdenas A, Campos J, Ehrenfeld P, Mezzano
S, Ruiz-Ortega M, Figueroa CD and Ardiles L: Up-regulation of the
kinin B2 receptor pathway modulates the TGF-β/Smad signaling
cascade to reduce renal fibrosis induced by albumin. Peptides.
73:7–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Campochiaro PA, Jerdan JA, Glaser BM,
Cardin A and Michels RG: Vitreous aspirates from patients with
proliferative vitreoretinopathy stimulate retinal pigment
epithelial cell migratio. Arch Ophthalmol. 103:1403–1405. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He S, Kuma SR, Zhou P, Krasnoperov V, Ryan
SJ, Gill PS and Hinton DR: Soluble EphB4 inhibition of PDGF-induced
RPE migration in vitro. Invest Ophthalmol Vis Sci. 51:543–552.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chan CM, Huang JH, Chiang HS, Wu WB, Lin
HH, Hong JY and Hung CF: Effects of (−)-epigallocatechin gallate on
RPE cell migration and adhesion. Mol Vis. 16:586–595.
2010.PubMed/NCBI
|
|
42
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saitoh M and Miyazawa K: Transcriptional
and post-transcriptional regulation in TGF-β-mediated
epithelial-mesenchymal transition. J Biochem. 151:563–571. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choi K, Lee K, Ryu SW, Im M, Kook KH and
Choi C: Pirfenidone inhibits transforming growth factor-β1-induced
fibrogenesis by blocking nuclear translocation of Smads in human
retinal pigmentepithelial cell line ARPE-19. Mol Vis. 18:1010–1020.
2012.PubMed/NCBI
|
|
45
|
Feng XH and Derynck R: Specificity and
versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev
Biol. 21:659–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Massagué J: TGF-β signalling in context.
Nat Rev Mol Cell Biol. 13:616–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang YC, Piek E, Zavadil J, Liang D, Xie
D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB and Böttinger
EP: Hierarchical model of gene regulation by transforming growth
factor beta. Proc Natl Acad Sci USA. 100:pp. 10269–10274. 2003;
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Saika S, Yamanaka O, Nishikawa-Ishida I,
Kitano A, Flanders KC, Okada Y, Ohnishi Y, Nakajima Y and Ikeda K:
Effect of Smad7 gene overexpression on transforming growth factor
beta-induced retinal pigment fibrosis in a proliferative
vitreoretinopathy mouse model. Arch Ophthalmol. 125:647–654. 2007.
View Article : Google Scholar : PubMed/NCBI
|
